Maximising the Use of HRE Focus on Hysterectomised Women

References

• Langer R. D., Barrett-Connor E. Extended hormone replacement: who should get it, and for how long. Geriatrics 1994; 49(12)20–291. Langer R. D., Barrett-Connor E. Extended hormone replacement: who should get it, and for how long. Geriatrics 1994; 49(12)20–29
   PubMed Web of Science ®Google Scholar
• Tang M.-X., Jacobs D., Stern Y., Marder K., Schofield P., Gurland B., Andrews H., Mayeux R. Effect of oestrogen during menopause and age of onset of Alzheimer's disease. Lancet 1996; 348: 429–4322. Tang M.-X., Jacobs D., Stern Y., Marder K., Schofield P., Gurland B., Andrews H., Mayeux R. Effect of oestrogen during menopause and age of onset of Alzheimer's disease. Lancet 1996; 348: 429–432
   PubMed Web of Science ®Google Scholar
• Studd J., Khastgir G. Hormone replacement after hysterectomy. The Management of the Menopause. Annual Review 1998, J. Studd. Parthenon, Carnforth 1998; 257–2703. Studd J., Khastgir G. Hormone replacement after hysterectomy. The Management of the Menopause. Annual Review 1998, J. Studd. Parthenon, Carnforth 1998; 257–270
   Google Scholar
• Siddle N., Sarrel P., Whitehead M. The effect of hysterectomy on the age of ovarian failure: identification of a subgroup of women with premature loss of ovarian function and literature review. Fertil. Steril. 1987; 47: 94–1004. Siddle N., Sarrel P., Whitehead M. The effect of hysterectomy on the age of ovarian failure: identification of a subgroup of women with premature loss of ovarian function and literature review. Fertil. Steril. 1987; 47: 94–100
   PubMed Web of Science ®Google Scholar
• Hreshchyshyn M. M., Hopkins A., Zylstra S., Anbar M. Effects of natural menopause, hysterectomy and oophorectomy on lumbar spine and femoral neck bone densities. Obstet. Gynecol. 1998; 72: 31–385. Hreshchyshyn M. M., Hopkins A., Zylstra S., Anbar M. Effects of natural menopause, hysterectomy and oophorectomy on lumbar spine and femoral neck bone densities. Obstet. Gynecol. 1998; 72: 31–38
   Google Scholar
• Rebar R. W., Spitzer I. B. The physiology and measurement of hot flushes. J. Obstet. Gynecol. 1987; 156: 1284–12886. Rebar R. W., Spitzer I. B. The physiology and measurement of hot flushes. J. Obstet. Gynecol. 1987; 156: 1284–1288
   Google Scholar
• Oldenhave A., Jaszmann L., Everaerd W. T., Haspels A. A. Hysterectomized women with ovarian conservation report more climacteric complaints than do normal climacteric women of similar age. Am. J. Obstet. Gynecol. 1993; 168: 765–7717. Oldenhave A., Jaszmann L., Everaerd W. T., Haspels A. A. Hysterectomized women with ovarian conservation report more climacteric complaints than do normal climacteric women of similar age. Am. J. Obstet. Gynecol. 1993; 168: 765–771
   PubMed Web of Science ®Google Scholar
• Limouzin-Lamothe M. A., Mairon N., Joyce C. R. B., Le Gal M. Quality of life after the menopause: influence of hormone replacement therapy. Am. J. Obstet. Gynecol. 1994; 170: 618–6248. Limouzin-Lamothe M. A., Mairon N., Joyce C. R. B., Le Gal M. Quality of life after the menopause: influence of hormone replacement therapy. Am. J. Obstet. Gynecol. 1994; 170: 618–624
   PubMed Web of Science ®Google Scholar
• National Center for Health Statistics. Vital statistics of the United States, 1987, Vol. II: Mortality, Part A. Public Health Service, Washington, DC 19909. National Center for Health Statistics. Vital statistics of the United States, 1987, Vol. II: Mortality, Part A. Public Health Service, WashingtonDC 1990
   Google Scholar
• Grady D., Rubin S. M., Petitti D. B., Fox C. S., Black D., Ettinger B., Ernster V. L., Cummings S. R. Hormone replacement therapy to prevent disease and prolong life in postmenopausal women. Ann. Intern. Med. 1992; 117: 1016–103710. Grady D., Rubin S. M., Petitti D. B., Fox C. S., Black D., Ettinger B., Ernster V. L., Cummings S. R. Hormone replacement therapy to prevent disease and prolong life in postmenopausal women. Ann. Intern. Med. 1992; 117: 1016–1037
   PubMed Web of Science ®Google Scholar
• Stevenson J. C. The metabolic and cardiovascular consequences of HRT. Br. J. Clin. Pract. 1995; 49(2)87–9011. Stevenson J. C. The metabolic and cardiovascular consequences of HRT. Br. J. Clin. Pract. 1995; 49(2)87–90
   PubMedGoogle Scholar
• Hassager C., Christiansen C. Blood pressure during oestrogen/progestogen substitution therapy in healthy postmenopausal women. Maturitas 1988; 9: 315–32312. Hassager C., Christiansen C. Blood pressure during oestrogen/progestogen substitution therapy in healthy postmenopausal women. Maturitas 1988; 9: 315–323
   PubMed Web of Science ®Google Scholar
• Henderson B. E., Paginini-Hill A., Ross R. K. Decreased mortality in users of estrogen replacement therapy. Arch. Intern. Med. 1991; 151: 75–7813. Henderson B. E., Paginini-Hill A., Ross R. K. Decreased mortality in users of estrogen replacement therapy. Arch. Intern. Med. 1991; 151: 75–78
   PubMed Web of Science ®Google Scholar
• Finucane F. F., Madans J. I. I., Bush T. L., Wolf P. H., Kleinman J. C. Decreased risk of stroke among postmenopausal hormone users: results from a national cohort. Arch. Intern, Med. 1993; 153: 73–7914. Finucane F. F., Madans J. I. I., Bush T. L., Wolf P. H., Kleinman J. C. Decreased risk of stroke among postmenopausal hormone users: results from a national cohort. Arch. Intern, Med. 1993; 153: 73–79
   PubMed Web of Science ®Google Scholar
• Maddox M. A. Women at midlife. Nurs. Clin. N. Am. 1992; 27(4)959–96915. Maddox M. A. Women at midlife. Nurs. Clin. N. Am. 1992; 27(4)959–969
   PubMed Web of Science ®Google Scholar
• Cardozo L. The role of oestrogens in urogynaecology: low-dose therapy. European Consensus Development Conference on Menopause, M. H. Birkhauser, H. Rozenbaum. ESKA, Paris 1996; 59–6616. Cardozo L. The role of oestrogens in urogynaecology: low-dose therapy. European Consensus Development Conference on Menopause, M. H. Birkhauser, H. Rozenbaum. ESKA, Paris 1996; 59–66
   Google Scholar
• Samsioe G., Jansson I., Mellstrom D., Svandborg A. Occurrence, nature and treatment of urinary incontinence in a 70 year old female population. Maturitas 1985; 7: 335–34217. Samsioe G., Jansson I., Mellstrom D., Svandborg A. Occurrence, nature and treatment of urinary incontinence in a 70 year old female population. Maturitas 1985; 7: 335–342
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative re-analysis of data from 51 epidemiological studies of 52, 705 women with breast cancer and 108, 411 women without breast cancer. Lancet 1997; 50: 1047–105918. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative re-analysis of data from 51 epidemiological studies of 52, 705 women with breast cancer and 108, 411 women without breast cancer. Lancet 1997; 50: 1047–1059
   Google Scholar
• Sturdee D. Summary. HRTand thromboembolism, D. Sturdee. Round table series, Royal Society of Medicine Press. 1997; 50: 39–4019. Sturdee D. Summary. HRTand thromboembolism, D. Sturdee. Round table series, Royal Society of Medicine Press. 1997; 50: 39–40
   Google Scholar
• Ryan P. J., Harrison R., Blake G. M., Fogelman I. Compliance with hormone replacement therapy after screening for post-menopausal osteoporosis. Br. J. Obstet. Gynaecol. 1992; 99: 325–32820. Ryan P. J., Harrison R., Blake G. M., Fogelman I. Compliance with hormone replacement therapy after screening for post-menopausal osteoporosis. Br. J. Obstet. Gynaecol. 1992; 99: 325–328
   PubMedGoogle Scholar
• Torgeson D. J., Donaldson C., Russell I. T., Reid D. M. Hormone replacement therapy: compliance and cost after screening for osteoporosis. Eur. J. Obstet. Gynecol. Reprod. Biol. 1995; 59: 57–6021. Torgeson D. J., Donaldson C., Russell I. T., Reid D. M. Hormone replacement therapy: compliance and cost after screening for osteoporosis. Eur. J. Obstet. Gynecol. Reprod. Biol. 1995; 59: 57–60
   PubMed Web of Science ®Google Scholar
• Cano A. Compliance to hormone replacement therapy in menopausal women controlled in a third level academic centre. Maturitas 1995; 20: 91–9922. Cano A. Compliance to hormone replacement therapy in menopausal women controlled in a third level academic centre. Maturitas 1995; 20: 91–99
   Web of Science ®Google Scholar
• Lutkie A. W. H. M., Hackel S., Van de Ven L. L. M. Long-term tolerability and efficacy of Fem7, a once-weekly transdermal system, in women with post-menopausal complaints. J. Clin. Res. 1998; 1: 161–17123. Lutkie A. W. H. M., Hackel S., Van de Ven L. L. M. Long-term tolerability and efficacy of Fem7, a once-weekly transdermal system, in women with post-menopausal complaints. J. Clin. Res. 1998; 1: 161–171
   Google Scholar
• Fraser I. S., Wang Y. New delivery systems for hormone replacement therapy. The Management of the Menopause. Annual Review 1998, J. Studd. Parthenon, Carnforth 1998; 101–11024. Fraser I. S., Wang Y. New delivery systems for hormone replacement therapy. The Management of the Menopause. Annual Review 1998, J. Studd. Parthenon, Carnforth 1998; 101–110
   Google Scholar
• Lufkin E. G., Ory S. J. Relative value of transdermal and oral estrogen therapy in various clinical situations. Mayo Clin. Proc. 1994; 69: 131–13525. Lufkin E. G., Ory S. J. Relative value of transdermal and oral estrogen therapy in various clinical situations. Mayo Clin. Proc. 1994; 69: 131–135
   PubMed Web of Science ®Google Scholar
• Corson S. L. A decade of experience with transdermal estrogen replacement therapy: overview of key pharmacologic and clinical findings. Int. J. Fertil. 1993; 38(2)79–9126. Corson S. L. A decade of experience with transdermal estrogen replacement therapy: overview of key pharmacologic and clinical findings. Int. J. Fertil. 1993; 38(2)79–91
   PubMedGoogle Scholar
• Crook D., Cust M. P., Gangar I., Worthington F. M., Hillard T. C., Stevenson J. C., Whitehead M. I., Wynn V. Comparison of transdermal and oral estrogeniprogestin hormone replacement therapy: effects on serum lipids and lipoproteins. Am. J. Obstet. Gynecol. 1992; 166: 950–95527. Crook D., Cust M. P., Gangar I., Worthington F. M., Hillard T. C., Stevenson J. C., Whitehead M. I., Wynn V. Comparison of transdermal and oral estrogeniprogestin hormone replacement therapy: effects on serum lipids and lipoproteins. Am. J. Obstet. Gynecol. 1992; 166: 950–955
   PubMed Web of Science ®Google Scholar
• Fox J., George A. J., Newton J. R., Parson A. D., Stuart G. K., Stuart J., Sturdee D. W. Effect of transdermal oestradiol on the haemostatic balance of menopausal women. Maturitas 1993; 18: 55–6428. Fox J., George A. J., Newton J. R., Parson A. D., Stuart G. K., Stuart J., Sturdee D. W. Effect of transdermal oestradiol on the haemostatic balance of menopausal women. Maturitas 1993; 18: 55–64
   PubMedGoogle Scholar
• Jensen J., Christiansen C. Effects of smoking on serum lipo-proteins and bone mineral content during postmenopausal hormone replacement therapy. Am. J. Obstet. Gynecol. 1988; 159: 820–82529. Jensen J., Christiansen C. Effects of smoking on serum lipo-proteins and bone mineral content during postmenopausal hormone replacement therapy. Am. J. Obstet. Gynecol. 1988; 159: 820–825
   PubMed Web of Science ®Google Scholar
• Roberts P.-J. Reported satisfaction among women receiving hormone replacement therapy in a dedicated general practice clinic and in a normal consultation. Br. J. Gen. Pract. 1995; 45: 79–8130. Roberts P.-J. Reported satisfaction among women receiving hormone replacement therapy in a dedicated general practice clinic and in a normal consultation. Br. J. Gen. Pract. 1995; 45: 79–81
   PubMed Web of Science ®Google Scholar